Biotechnology
Biopharmaceutical
Pharmaceutical
Fate Therapeutics
$18.579876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$18.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.98 (5.57%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell FATE and other stocks, options, ETFs, and crypto commission-free!
About FATE
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Employees
104
Headquarters
San Diego, California
Founded
2007
Market Cap
1.21B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
774.48K
High Today
$18.77
Low Today
$17.78
Open Price
$17.80
Volume
562.05K
52 Week High
$22.82
52 Week Low
$10.78
Collections
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Therapy
Technology
2013 IPO
FATE News
Price Paid on Robinhood
53% Higher
Right Now
52 Week Low
$8.35
Average Price Paid
$12.15
52 Week High
$19.11
Analyst Ratings
92%
of 12 ratings
Buy
92%
Hold
8%
Sell
0%
FATE Earnings
-$0.37
-$0.32
-$0.27
-$0.22
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.33 per share
Actual
-$0.36 per share